Generalizability of findings from cardiovascular outcomes trials (CVOTs) to patients with type 2 diabetes (T2D) in clinical practice is unknown. We assessed the proportions of patients in the Diabetes Collaborative Registry who would have met enrolment criteria for pivotal CVOTs of sodium-glucose co-transporter-2 inhibitors (SGLT2is): EMPA-REG OUTCOME, CANVAS, DECLARE and VERTIS CV. In 172 643 patients, mean [standard deviation (SD)] age and HbA1c were 68.1 (11.8) years and 7.8% (2.2), respectively; 56.8% of patients were men and SGLT-2i use was 4.4%. Atherosclerotic cardiovascular disease (ASCVD) prevalence was 64.3% and mean 10-year ASCVD risk was 28.6% in patients without ASCVD. Proportions of patients eligible for CVOTs ranged from 26% (EMPA-REG OUTCOME) to 44% (DECLARE); 48% of patients were ineligible for all CVOTs. Mean (SD) ASCVD risk was 25.4% (22.6), 32.1% (20.6) and 37.7% (19.4) in patients eligible for no, one or two CVOTs, respectively. SGLT-2i use was low in patients eligible for no CVOTs (3.5%) and at least one CVOT (5.2%). In conclusion, applicability of CVOT results to patients with T2D in clinical practice varies based on trial eligibility criteria. 1 Three CVOTs showed significant CV benefits of the sodium-glucose cotransporter-2 inhibitors (SGLT-2is) empagliflozin, canagliflozin and dapagliflozin in patients with T2D. [2] [3] [4] Real-world data from CVD-REAL studies suggest a class effect, 5 and one CVOT of ertugliflozin is ongoing. 6 However, in order to accrue a sufficient number of CV events in a timely manner, CVOTs generally enrol patients at higher CV risk than a patient with T2D seen in routine clinical practice. Therefore, the generalizability of CVOT findings to the broader population of patients with T2D is unknown.
48% of patients were ineligible for all CVOTs. Mean (SD) ASCVD risk was 25.4% (22.6), 32.1% (20.6) and 37.7% (19.4) in patients eligible for no, one or two CVOTs, respectively. SGLT-2i use was low in patients eligible for no CVOTs (3.5%) and at least one CVOT (5.2%). In conclusion, applicability of CVOT results to patients with T2D in clinical practice varies based on trial eligibility criteria. 1 Three CVOTs showed significant CV benefits of the sodium-glucose cotransporter-2 inhibitors (SGLT-2is) empagliflozin, canagliflozin and dapagliflozin in patients with T2D. [2] [3] [4] Real-world data from CVD-REAL studies suggest a class effect, 5 and one CVOT of ertugliflozin is ongoing. 6 However, in order to accrue a sufficient number of CV events in a timely manner, CVOTs generally enrol patients at higher CV risk than a patient with T2D seen in routine clinical practice. Therefore, the generalizability of CVOT findings to the broader population of patients with T2D is unknown.
The Diabetes Collaborative Registry (DCR) is the first US crossspecialty outpatient practice database designed to track and improve the quality of care for patients with diabetes across primary and specialty care settings. 7 Initiated in 2014 as a collaboration between endocrinology, primary care and cardiology professional societies, the registry collects relevant data from electronic health records of patients within participating practices. Demographic and clinical characteristics of the analytic cohort were described. Selected data including A1C range and history of chronic kidney disease (CKD) and CV disease (CVD) ( Table 1) were extracted from the analytic cohort. These data were cross-tabulated with major determinants of eligibility from the four CVOTs examined (Table S1 ), in order to estimate the percentages of patients who were eligible for individual, all, or none of the CVOTs. Where no value was recorded for CKD-and CVD-related variables, it was assumed that the condition was not present.
The 10-year atherosclerotic CVD (ASCVD) risk for patients without established CVD was calculated using the American College of Cardiology ASCVD risk estimator. 9 In addition, the 5-year risk of CVD, including coronary heart disease and stroke, was calculated using the method devised by Pocock et al. 8 Briefly, this method calculates a risk score based on 11 key risk factors: age, sex, smoking, systolic blood pressure, total cholesterol, height, creatinine, history of myocardial infarction, history of stroke, diabetes, and left ventricular hypertrophy. When calculating the 5-year risk of CVD, missing data were estimated using simple imputation. Data on left ventricular hypertrophy are not currently collected in the DCR, so this risk factor was set to zero for all patients.
| RESULTS
The analytic cohort consisted of 172 643 DCR patients with evaluable data who met the study inclusion criteria (Table 1) . Within this cohort, 56.8% of patients were men; mean [standard deviation (SD)] age and A1C were 68.1 (11.8) years and 7.8% (2.2), respectively; 4.4% of patients were using SGLT-2is. In total, 64.3% of patients had ASCVD, and mean (SD) 10-year ASCVD risk was 28.6% in patients without established ASCVD. Overall, the mean (SD) risk of CVD death within 5 years was 6.7% (8.0).
The proportions of patients meeting CVOT inclusion criteria ranged from 26% for EMPA-REG OUTCOME to 44% for DECLARE ( Figure 1A ). Mean age, A1C and proportions of men and SGLT-2i use were similar between the cohorts of patients eligible for each CVOT ( (Table S2) . SGLT-2i use was 3.5% and 5.2% in patients eligible for no CVOTs and at least one CVOT, respectively.
| DISCUSSION
Data from the EMPA-REG OUTCOME, CANVAS, and DECLARE CVOTs showed a significant benefit of the SGLT-2is empagliflozin, canagliflozin and dapagliflozin in decreasing the risk of CV events in patients with T2D. [2] [3] [4] However, the applicability of the findings from
CVOTs to patients with T2D in the real world is not certain, given the selective populations enrolled in CVOTs.
The inclusivity of all CVOTs assessed in our analysis was less than 50%. Despite DECLARE being the most inclusive CVOT, 56% of the DCR cohort in the present study did not meet eligibility criteria for this trial. Nonetheless, this finding suggests that the results from DECLARE may still be applicable to a large proportion of patients with T2D in the general population. The EMPA-REG OUTCOME and CAN-VAS eligibility criteria minimally reflected the general T2D population, which was probably attributable to these trials predominantly enrolling patients with prior CVD (the proportion of patients with a history of CVD was 99% and 66% in EMPA-REG OUTCOME and CANVAS, respectively). 2, 3 In contrast, the majority of patients enrolled in DECLARE (59%) did not have established CVD.
Our results are similar to findings from a large European observational study where the proportions of patients eligible for EMPA-REG OUTCOME, CANVAS, DECLARE and VERTIS CV were 21%, 34%, 59% and 17%, respectively. 10 A recent meta-analysis of 34 322
patients from EMPA-REG OUTCOME, the CANVAS programme and DECLARE concluded that the collective modest benefit of SGLT-2is in history of CAD, MI, PCI, CABG, stable angina, PAD, stroke, TIA, carotid stenting or carotid endarterectomy, or no CV history in patients aged >55 years (men) or >60 years (women) with at least one CV risk factor the reduction of atherothrombotic CV events was primarily limited to patients with established CVD. 11 However, patients with T2D and a broad CV risk profile enrolled in DECLARE experienced significant reductions in the composite of CV death or heart failure hospitalizations when treated with dapagliflozin compared with placebo. T2D and established ASCVD, and also for patients with T2D and either heart failure or CKD. 19 Given that these guidelines may alter prescribing patterns in patients with T2D, SGLT-2i use should be evaluated over time to detect any change in the frequency of prescribing of these agents.
Study limitations include the high rates of missing data for some parameters (eg, urine albumin and high-density lipoprotein cholesterol) in the DCR, which could have led to underestimation of trial eligibility. Conversely, use of selected key CVOT inclusion criteria in the analysis and greater prevalence of CVD in patients from a mostly cardiology practice-based registry increased the probability of overestimating trial eligibility for the general population of patients with T2D. Given that the DCR is continually enrolling practices, the CV risk profile of patients may change in response to the proportion of cardiology practices in the registry.
Future studies of a similar nature to this one will allow an assessment of whether the CVOT eligibility of DCR patients changes as a consequence.
In conclusion, the applicability of CVOT results to the broader population of patients with T2D in clinical practice varies based on trial eligibility criteria. Findings from the present study will assist clinicians in assessing the representativeness of CVOT trial populations to the overall population of patients with T2D in clinical practice.
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